Venetoclax/Rituximab Combo Approved for CLL/SLL
Jun 18, 2018
FDA warns, however, about the possibility of TLS due to rapid tumor cell destruction.
Recent Content
Bevacizumab Rechallenge Benefit in Recurrent Ovarian Cancer?
Jun 18, 2018
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 Inhibitor
Jun 18, 2018
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Immunotherapy for Prostate Cancer: Where Do We Go From Here?—PART 2: Checkpoint Inhibitors, Immunotherapy Combinations, Tumor Microenvironment Modulation, and Cellular Therapies
Jun 15, 2018
Here we focus on alternative methods of harnessing both adaptive and innate antitumor immunity to target prostate cancer cells, and look ahead to provide a perspective on how this growing collection of immunotherapeutic approaches may ultimately be combined to target prostate cancer from a variety of angles.
The Use of Surgery and Radiotherapy as Treatment of Regional Nodes in Breast Cancer Patients
Jun 15, 2018
This article discusses the ways in which pathologic regional nodal status affects clinical decisions about locoregional and systemic treatment, reviews published literature and guidelines, and aims to provide a practical perspective on treatment approach in the face of a broad range of data and recommendations.
Understanding the Benefits of Acupuncture Treatment for Cancer Pain Management
Jun 15, 2018
This article reviews how acupuncture is thought to work, data on acupuncture for managing pain caused by cancer or by cancer treatment, how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.
How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis
Jun 15, 2018
Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer
Jun 15, 2018
A 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
In DLBCL, Polatuzumab Combo Yields ‘Marked Improvement’ in CR, PFS, OS
Jun 15, 2018
Polatuzumab vedotin administered with bendamustine and rituximab significantly improved PET-based CR rates, PFS, and OS in DLBCL but not FL.
COUNTERPOINT: Does Chemoimmunotherapy Still Have a Role in CLL?
Jun 15, 2018
Elimination of chemotherapy from our combination regimens should be a shared goal among researchers that will move us a step closer to more patient-friendly and scientifically driven therapies for CLL.
